Abstract
CANCER is more common in transplant recipients than in the general population. The reported incidence of malignant tumors after renal transplantation is 14 to 500 times higher than the rate in the general population. The prevalence of malignant tumors in different series of renal recipients ranges from 1 to 16% (mean 4%) and varies with type of organ transplant, age of the recipient, individual transplant center, and type of immunosuppression (IS). Other possible contributing factors are chronic antigenic stimulation, oncogenic virus activation, genetic susceptibility, and uremia. In this article, we describe 50 cases of malignant tumor development in renal transplant recipients who were treated with different immunosuppressive protocols in the Transplantation Center at Baskent University Faculty of Medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
